The Amy Mcbride Wendell invests in 13,333 by purchasing AxoGen Inc. (AXGN) Stock shares

The Amy Mcbride Wendell invests in 13,333 by purchasing AxoGen Inc. (AXGN) Stock shares

AxoGen Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell bought 13,333 shares of AxoGen stock in a transaction on Friday, October 7th. The shares were acquired at an average price of $7.50 per share, for a total transaction of $99,997.50. Following the completion of the acquisition, the director now owns 13,333 shares of the company’s stock, valued at approximately $99,997.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

AxoGen Inc. (NASDAQ:AXGN) remained flat at $8.72 on Friday. The stock had a trading volume of 292,026 shares. The firm has a 50 day moving average price of $8.74 and a 200 day moving average price of $6.97. AxoGen Inc. has a 12-month low of $4.08 and a 12-month high of $9.88. The stock’s market cap is $262.75 million.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.03. AxoGen had a negative return on equity of 193.60% and a negative net margin of 37.90%. On average, equities analysts forecast that AxoGen Inc. will post ($0.40) earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Waddell & Reed Financial Inc. purchased a new position in shares of AxoGen during the second quarter worth approximately $1,371,000. State Street Corp purchased a new position in shares of AxoGen during the second quarter worth approximately $1,885,000. Rhumbline Advisers purchased a new position in shares of AxoGen during the second quarter worth approximately $132,000. Teachers Advisors Inc. purchased a new position in shares of AxoGen during the second quarter worth approximately $267,000. Finally, TFS Capital LLC purchased a new position in shares of AxoGen during the second quarter worth approximately $113,000. Institutional investors own 57.99% of the company’s stock.

Separately, Wedbush reiterated an “outperform” rating and set a $10.00 target price (up from $9.00) on shares of AxoGen in a report on Thursday, August 4th.

Related posts

Leave a Comment